

Companion Diagnostics in der Tumortherapie

Martin Hergersberg

Referenzen

1. Lemery S et al (2017) First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. *NEJM* 377:1409-1412.
2. Heinimann K (2008) Molekulargenetische Diagnostik bei HNPCC (Hereditäres Kolorektal-Karzinom ohne generalisierte Polypose). *Schweizerische Ärztezeitung* 36:2009–2012.
3. Sawyers C (2016) Dorcas Cummings Lecture. *Cold Spring Harb Symp Quant Biol* 81:291-295.
4. Horn L et al (2017) Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). *J Clin Oncol*. JCO2017743062. doi: 10.1200/JCO.2017.74.3062.
5. Chakravarty D et al (2017) OncoKB: A Precision Oncology Knowledge Base. *JCO Precis Oncol*. doi: 10.1200/PO.17.00011.
6. McNeil C (2015) NCI-MATCH launch highlights new trial design in precision-medicine era. *J Natl Cancer Inst* 107.
7. Cunanan KM et al (2017) Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. *J Clin Oncol* 35:271-273.
8. Stupp R (2016) MyPathway: der neue Weg in der Krebsmedizin? *Leading Opinions Hämatologie & Onkologie* 2016/4: 38-40.
9. Obermeyer Z, Lee TH (2017) Lost in Thought — The Limits of the Human Mind and the Future of Medicine. *NEJM* 377:1209-1211
10. Prasad V et al (2017) The high price of anticancer drugs: origins, implications, barriers, solutions. *Nat Rev Clin Oncol* 14:381-390.
11. Fey MF (2014) Die modern Krebsmedizin: weniger wäre manchmal mehr. *Therapeutische Umschau* 71:765-770.
12. Prasad V (2017) Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers. *Nat Rev Clin Oncol*. 2017 Oct 4. doi: 10.1038/nrclinonc.2017.156.